IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Foresight Global Investors Inc.

Foresight Global Investors Inc. trimmed its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 12.3% in the 4th quarter, HoldingsChannel reports. The firm owned 5,413 shares of the medical research company’s stock after selling 762 shares during the period. IQVIA makes up 0.7% of Foresight Global Investors Inc.’s investment portfolio, making the stock its 25th biggest position. Foresight Global Investors Inc.’s holdings in IQVIA were worth $1,252,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. E Fund Management Co. Ltd. acquired a new stake in IQVIA in the fourth quarter valued at approximately $214,000. National Pension Service lifted its position in shares of IQVIA by 2.3% during the 4th quarter. National Pension Service now owns 367,815 shares of the medical research company’s stock worth $85,105,000 after purchasing an additional 8,259 shares during the last quarter. Meridian Wealth Advisors LLC grew its stake in shares of IQVIA by 5.5% during the fourth quarter. Meridian Wealth Advisors LLC now owns 14,847 shares of the medical research company’s stock worth $3,435,000 after purchasing an additional 768 shares in the last quarter. Everpar Advisors LLC purchased a new position in IQVIA in the fourth quarter valued at $231,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in IQVIA by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,160,716 shares of the medical research company’s stock worth $268,566,000 after buying an additional 28,598 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on IQV shares. Truist Financial cut their target price on IQVIA from $297.00 to $292.00 and set a “buy” rating on the stock in a research report on Friday, May 3rd. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a report on Monday, February 26th. Robert W. Baird cut their price target on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating on the stock in a research note on Friday, May 3rd. UBS Group raised their price objective on IQVIA from $240.00 to $300.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Finally, StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a report on Friday, February 16th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $257.57.

IQVIA Price Performance

NYSE:IQV traded up $1.32 during trading hours on Thursday, reaching $229.20. 643,740 shares of the company traded hands, compared to its average volume of 961,353. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The stock has a market cap of $41.76 billion, a P/E ratio of 31.31, a P/E/G ratio of 2.16 and a beta of 1.52. The firm’s 50-day moving average is $242.48 and its 200-day moving average is $225.08. The company has a debt-to-equity ratio of 2.02, a current ratio of 0.88 and a quick ratio of 0.88.

IQVIA (NYSE:IQV) last announced its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share for the quarter, beating the consensus estimate of $2.82 by $0.02. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The firm had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the previous year, the company posted $2.54 EPS. The firm’s revenue for the quarter was up 3.5% on a year-over-year basis. Equities research analysts expect that IQVIA Holdings Inc. will post 10.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the sale, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Ari Bousbib sold 31,678 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the sale, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Eric Sherbet sold 1,000 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the transaction, the insider now directly owns 20,836 shares in the company, valued at approximately $5,031,894. The disclosure for this sale can be found here. In the last three months, insiders sold 41,285 shares of company stock valued at $10,331,003. Company insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.